Citadel Advisors’s abrdn Life Sciences Investors HQL Stock Holding History

Citadel Advisors’s Portfolio HQL Stock Details HQL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$287K	Buy	+14,356	New	+$254K	﹤0.01%	11210

Other funds holding HQL

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

PCM

Penserra Capital Management Orinda, California $13B AUM 71.84% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return

NIM

Needham Investment Management New York $3.33B AUM 163.16% 1-Year Est. Return

FHA

Flagship Harbor Advisors Boston, Massachusetts $2.61B AUM 23.21% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

AAM

Advisors Asset Management Monument, Colorado $6.56B AUM 35.09% 1-Year Est. Return

1WA

180 Wealth Advisors Federal Way, Washington $997M AUM 47.84% 1-Year Est. Return

Citadel Advisors's HQL Position: Q2 2026 in Review

Citadel Advisors opened a new position in abrdn Life Sciences Investors (HQL) in Q2 2026: 14,356 shares worth $287K. The stake represents ﹤0.01% of the portfolio and ranks #11210 among its holdings.

83 funds tracked by Wall St. Rank hold HQL as of Q2 2026.

Citadel Advisors held 14,356 shares of abrdn Life Sciences Investors worth $287K as of Q2 2026.
abrdn Life Sciences Investors was a new Citadel Advisors position in Q2 2026.
abrdn Life Sciences Investors made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #11210 holding.
83 funds tracked by Wall St. Rank held abrdn Life Sciences Investors as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.